Horizon Pharma, Inc. (HZNP), incorporated on March 23, 2010, is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. On April 23, 2011, the United States Food and Drug Administration, approved
DUEXIS (formerly HZT-501), a tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill. The Company’s other product,
LODOTRA (NP-01), is a programmed release formulation of low-dose prednisone that is marketed in Europe by the Company’s distribution partner, Mundipharma International Corporation Limited (Mundipharma). As of December 31, 2010, Horizon completed multiple Phase III clinical trials of LODOTRA. In addition to these product candidates, the Company has a pipeline of earlier-stage product candidates to treat pain-related diseases and chronic inflammation. On April 1, 2010, Horizon effected a recapitalization and acquisition pursuant to which Horizon Pharma, Inc. became a holding company, that operates through its wholly owned subsidiaries, Horizon Pharma USA, Inc. (formerly Horizon Therapeutics, Inc.) and Horizon Pharma AG (formerly Nitec Pharma AG (Nitec)).
The company was founded in 2005 and is headquartered in Deerfield, Illinois.
weekly chart since the IPO in 2011 thru June 2013
Address
Suite 520, 520 Lake Cook Road
DEERFIELD, IL 60062
United States
Key stats and ratios
|
| Net profit margin | -241.75% | -447.20% |
| Operating margin | -202.20% | -401.76% |
| EBITD margin | - | -373.55% |
| Return on average assets | -48.88% | -59.51% |
| Return on average equity | -93.57% | -115.60% |
| Employees | 249 |
No comments:
Post a Comment